10275
Scheme 2.
Acknowledgements
The authors would like to thank the National Science Council of the Republic of China for
financial support.
References
1. (a) Moreia, A. L.; Corral, L. G.; Ye, W.; Johnson, B. A.; Stirling, D.; Muller, G. W.; Freedman, V. H.; Kaplan,
G. AIDS Res. Hum. Retoviruses 1997, 13, 857. (b) Dawson, N.; Figg, W. D.; Brawley, O. W.; Bergan, R.; Cooper,
M. R.; Senderowicz, A.; Headlee, D.; Steinberg, S. M.; Sutherland, M.; Patronas, N.; Sausville, E.; Linehan, W.
M.; Reed, E.; Sartor, O. Chin. Cancer Res. 1998, 4, 37. (c) Waelbroeck, M.; Lazareno, S.; Plaff, O.; Friebe, T.;
Tastoi, M.; Mutschler, E.; Lambert, G. Br. J. Pharmacol 1996, 119, 1319. (d) Park, M.; Lee, J.; Choi, J. Bioorg.
Med. Chem. Lett. 1996, 6, 1297.
2. (a) Nazar, F.; Pham-Huy, C.; Galons, H. Tetrahedron Lett. 1999, 40, 3697. (b) Leung, C. S.; Rowlands, M. G.;
Jarman, M.; Foster, A. B.; Griggs, L. J.; Wilman, D. E. V. J. Med. Chem. 1987, 30, 1550. (c) Knabe, J.; Wahl, S.
Arch. Pharm. 1987, 330, 1032. (d) Polonski, T. J. Chem. Soc., Perkin Trans. 1 1988, 639. (e) Kim, M. H.; Patel,
D. V. Tetrahedron Lett. 1994, 35, 5603. (f) Robin, S.; Zhu, J.; Galons, H.; Pham-Huy, C.; Claude, J. R.; Tomas,
A.; Viossat, B. Tetrahedron: Asymmetry 1995, 6, 1249. (g) Zhu, J.; Pham-Huy, C.; Lemoine, P.; Tomas, A.;
Galons, H. Heterocycles 1996, 43, 1923.
3. (a) Bushell, S. M.; Crump, J. P.; Lawrence, N. J.; Pineau, G. Tetrahedron 1998, 54, 2269. (b) Achmatowicz, O.;
Malinowska, I.; Szechner, B.; Maurin, J. K. Tetrahedron 1997, 53, 7917. (c) Fadel, A.; Garciaargote, S.
Tetrahedron: Asymmetry 1996, 7, 1159. (d) Fogliato, G.; Fronza, G.; Fuganti, C.; Grasselli, P.; Servi, S. J. Org.
Chem. 1995, 60, 5693.
1
4. The H and 13C NMR spectra of 24, in agreement with the literature,3d prove the regioselectivity of alkylation of
19.
5. (a) Hartmann, R. W.; Batzl, C.; Pongratz, T. M.; Mannschreck, A. J. Med. Chem. 1992, 35, 2210 and references
cited therein. (b) Harvey, H. A.; Lipton, A.; Santin, R. J. Cancer Res. (suppl.) 1982, 42, 3261.
1
6. Selected spectral data of 7: H NMR (300 MHz, CDCl3): l 7.52 (d, J=8.1 Hz, 2H), 7.25–7.32 (m, 7H), 5.03 (d,
J=13.8 Hz, 1H), 4.86 (d, J=13.8 Hz, 1H), 4.05–4.07 (m, 1H), 3.20–3.38 (m, 1H), 2.68–2.82 (m, 2H), 2.43 (s, 3H),
2.20–2.40 (m, 1H).
1
Selected spectral data of 15: H NMR (300 MHz, CDCl3): l 7.56 (d, J=7.8 Hz, 2H), 7.37 (d, J=4.5 Hz, 2H),
7.26–7.32 (m, 5H), 7.19 (s, 1H), 6.20 (s, 1H), 6.01 (d, J=2.7 Hz, 1H), 5.07 (d, J=14.4 Hz, 1H), 4.90 (d, J=14.4
Hz, 1H), 4.34–4.38 (m, 2H), 3.69 (dd, J=6.3, 18.0 Hz, 1H), 3.09 (d, J=18.0 Hz, 1H), 2.45 (s, 3H).
Selected spectral data of 19: 1H NMR (300 MHz, CDCl3): l 7.86 (d, J=8.1 Hz, 4/9H), 7.55 (d, J=8.4 Hz, 14/9H),
7.11–7.39 (m, 12H), 5.07 (d, J=13.8 Hz, 1H), 4.95 (d, J=13.8 Hz, 1H), 4.90 (d, J=2.7 Hz, 2/9H), 4.51 (dd,